Cas:55690-60-3 5-Methoxybenzothiazole-2-thiol manufacturer & supplier

We serve Chemical Name:5-Methoxybenzothiazole-2-thiol CAS:55690-60-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-Methoxybenzothiazole-2-thiol

Chemical Name:5-Methoxybenzothiazole-2-thiol
CAS.NO:55690-60-3
Synonyms:5-methoxy-3H-1,3-benzothiazole-2-thione;EINECS 259-755-1;MFCD00185941
Molecular Formula:C8H7NOS2
Molecular Weight:197.27700
HS Code:2934999090

Physical and Chemical Properties:
Melting point:190-193ºC
Boiling point:340.8ºC at 760 mmHg
Density:1.44g/cm3
Index of Refraction:1.728
PSA:89.16000
Exact Mass:196.99700
LogP:2.59360

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-methoxy-3H-1,3-benzothiazole-2-thione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00185941 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00185941 Use and application,EINECS 259-755-1 technical grade,usp/ep/jp grade.


Related News: Nearly all patients who got the vaccine developed antibodies designed to head off the spread of abnormal tau while leaving healthy tau proteins intact, Novak said. 5-Methoxybenzothiazole-2-thiol manufacturer Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies. 5-Methoxybenzothiazole-2-thiol supplier Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies. 5-Methoxybenzothiazole-2-thiol vendor Nearly all patients who got the vaccine developed antibodies designed to head off the spread of abnormal tau while leaving healthy tau proteins intact, Novak said. 5-Methoxybenzothiazole-2-thiol factory China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.